In this regard, data from the MANTICORE-101 study (Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research) have clarified the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril versus the β-blocker bisprolol in patients with early diagnosis of HER2 positive breast cancer undergoing treatment with trastuzumab [421]. The gene discussed is ACE; the disease is breast cancer.